Home > Cardiology > ACC 2019 > Arrhythmias and Clinical Electrophysiology > Less bleeding and fewer hospitalisations with antithrombotic regimen with apixaban without aspirin

Less bleeding and fewer hospitalisations with antithrombotic regimen with apixaban without aspirin

Conference
ACC 2019
Trial
AUGUSTUS

Results from the AUGUSTUS trial show that atrial fibrillation (AF) patients with recent acute coronary syndrome (ACS) and/or percutaneous coronary intervention (PCI) who receive a P2Y12 inhibitor experience less bleeding and fewer hospitalisations without significant differences in ischaemic events with an antithrombotic regimen that includes apixaban, without aspirin, than with regimens that include a vitamin K antagonist (VKA), aspirin, or both [1].

AUGUSTUS is an international, multicentre, randomised trial with a 2x2 factorial design to compare apixaban + aspirin or placebo with a VKA + aspirin or placebo in patients with AF who develop ACS and/or undergo PCI and are receiving a P2Y12 inhibitor. As such, it is the largest and only prospective randomised trial to investigate efficacy and safety of aspirin vs placebo with either non-VKA or VKA oral anticoagulation and a P2Y12 inhibitor for all patients.

Primary outcome of the study was the composi...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on